AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27469294 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diabetic)
Number of subjects: 87
Study 26659936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% A/BPO
Number of subjects: 252
Study 26659936 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% A/BPO
Number of subjects: 252
Study 26659936 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 252
Study 22824858 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm, humidified CO2 gas insufflation (37°C, 98% relative humidity)
Number of subjects: 190
Study 22824858 — intervention group
Group type: COMPARATOR
Intervention: Standard room temperature CO2 gas insufflation (20°C, 0% relative humidity)
Number of subjects: 190
Study 22824858 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm, humidified CO2 gas insufflation
Number of subjects: 190
Study 22824858 — intervention group
Group type: COMPARATOR
Intervention: Standard room temperature CO2 gas insufflation
Number of subjects: 190
Study 20848528 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease (IBD) patients with active disease
Number of subjects: 422
Study 20848528 — intervention group
Group type: COMPARATOR
Intervention: Chronic liver disease (CLD) patients
Number of subjects: 422
Study 20848528 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients with slight disease activity
Number of subjects: 422
Study 20848528 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients with moderate/severe disease activity
Number of subjects: 422
Study 20848528 — intervention group
Group type: COMPARATOR
Intervention: General population (GP)
Number of subjects: 422
Study 20848528 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients in remission
Number of subjects: 422
Study 18435187 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper Seal (Group 1)
Number of subjects: 56
Study 18435187 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (Group 2)
Number of subjects: 56
Study 18435187 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper Seal without removal (Group 3)
Number of subjects: 56
Study 18435187 — intervention group
Group type: COMPARATOR
Intervention: Negative control (Group 4)
Number of subjects: 56
Study 16528645 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI)
Number of subjects: 120
Study 16528645 — intervention group
Group type: COMPARATOR
Intervention: No MEI (Control group)
Number of subjects: 120
Study 12777590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQ)
Number of subjects: 525
Study 12777590 — intervention group
Group type: COMPARATOR
Intervention: Control group (other antibiotics)
Number of subjects: 525
Study 10711911 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg)
Number of subjects: 65
Study 10711911 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (4-10 mg)
Number of subjects: 65
Study 10711911 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg)
Number of subjects: 65
Study 9059196 — intervention group
Group type: EXPERIMENTAL
Intervention: Command and information tape (n = 34)
Number of subjects: 68
Study 9059196 — intervention group
Group type: COMPARATOR
Intervention: Radio static (n = 34)
Number of subjects: 68
Study 9059196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (command and information tape and radio static)
Number of subjects: 68
Study 1422752 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler colour flow imaging (DCFI)
Number of subjects: 30
Study 3919555 — intervention group
Group type: EXPERIMENTAL
Intervention: bepridil (400 mg once a day)
Number of subjects: 15
Study 31169354 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel (Stratacel®; Stratpharma) applied twice a day for 7 days
Number of subjects: 10
Study 31169354 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum-based ointment applied twice a day for 7 days
Number of subjects: 10
Study 29431785 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucono‐delta‐lactone (GDL) 2000 mg day‐1
Number of subjects: 40
Study 27352486 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetration acupuncture at acupoints of GV and bladder meridian on head (Wuchu to Chengguang, Tongtian to Luoque, Shenting to Xinhui, Qianding to Baihui, Houding to Qiangjian)
Number of subjects: 110
Study 27352486 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture and conventional western medication (both groups)
Number of subjects: 110
Study 27352486 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (acupuncture)
Number of subjects: 110
Study 25090820 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsedated transnasal endoscopy (TNE)
Number of subjects: 400
Study 25090820 — intervention group
Group type: COMPARATOR
Intervention: Unsedated transoral endoscopy (TOE)
Number of subjects: 400
Study 22013100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting normoglycemia (80‐110 mg/dl)
Number of subjects: 0
Study 22013100 — intervention group
Group type: COMPARATOR
Intervention: Tolerating hyperglycemia up to 215 mg/dl
Number of subjects: 0
Study 20502909 — intervention group
Group type: EXPERIMENTAL
Intervention: High myopes
Number of subjects: 66
Study 17728050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil as monotherapy
Number of subjects: 0
Study 17728050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil in combination with SSRI (paroxetine)
Number of subjects: 0
Study 17728050 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 0
Study 17728050 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetics
Number of subjects: 0
Study 15914256 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physical therapy plus 4 music therapy sessions
Number of subjects: 65
Study 15914256 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical therapy alone
Number of subjects: 65
Study 12022321 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strengthening program
Number of subjects: 68
Study 12022321 — intervention group
Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 68
Study 10768630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone sodium succinate treatment
Number of subjects: 100
Study 10768630 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 100
Study 8829312 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (40 mg/day orally in the evening, starting 7 days prior to cytokine injection)
Number of subjects: 116
Study 8829312 — intervention group
Group type: COMPARATOR
Intervention: Cytokine alone (IL-2: 3 x 10(6) IU/day s.c. every day, 6 days/week for 4 weeks; TNF: 0.75 mg/day i.v. for 5 days)
Number of subjects: 116
Study 1313875 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.1 g daily fibre supplementation
Number of subjects: 0
Study 1313875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3881913 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 62
Study 3881913 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 62
Study 3881913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 62
Study 3881913 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term Verapamil therapy
Number of subjects: 62
Study 3881913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31344685 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 5000 IU daily
Number of subjects: 96
Study 31344685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 29901760 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (LEU; 10 g milk protein with 3 g total l-leucine)
Number of subjects: 22
Study 29901760 — intervention group
Group type: COMPARATOR
Intervention: Whey Protein Isolate (WPI; 25 g WPI with 3 g l-leucine)
Number of subjects: 22
Study 26118849 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Number of subjects: 0
Study 26118849 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing an ankle brace
Number of subjects: 0
Study 26118849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training and bracing
Number of subjects: 0
Study 26118849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracing or combined bracing and NM training
Number of subjects: 0
Study 24845198 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 78
Study 24845198 — intervention group
Group type: EXPERIMENTAL
Intervention: Acapella device
Number of subjects: 78
Study 22177390 — intervention group
Group type: EXPERIMENTAL
Intervention: Online guided self-help program for BED
Number of subjects: 92
Study 22177390 — intervention group
Group type: COMPARATOR
Intervention: Pure dietary subtype
Number of subjects: 92
Study 19960492 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) with dose escalation (20-60 mg/day)
Number of subjects: 301
Study 18728660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib combined with capecitabine
Number of subjects: 0
Study 15968676 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer weighted imaging using cerebrospinal fluid as intersubject normalization reference (MTCSF imaging)
Number of subjects: 0
Study 15968676 — intervention group
Group type: COMPARATOR
Intervention: Magnetization transfer ratio (MTR)
Number of subjects: 0
Study 12891211 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g of fish oil daily for 12 weeks
Number of subjects: 84
Study 12891211 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil daily for 12 weeks
Number of subjects: 84
Study 10684161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate (60 mg elemental Fe) daily
Number of subjects: 203
Study 10684161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate (60 mg elemental Fe) intermittently (three times a week)
Number of subjects: 203
Study 10684161 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 203
Study 9102018 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoendoscopy-assisted saphena occlusion (VASO)
Number of subjects: 0
Study 9102018 — intervention group
Group type: COMPARATOR
Intervention: Crossectomy, dissection of perforating veins and occlusion of the saphena by endoscopic control
Number of subjects: 0
Study 30217371 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M 80 mg
Number of subjects: 2630
Study 30217371 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M/CLD 40/25 mg
Number of subjects: 2630
Study 30217371 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M/CLD 80/25 mg
Number of subjects: 2630
Study 27169436 — intervention group
Group type: EXPERIMENTAL
Intervention: Community exercise program (year-long, at least twice per week, supervised by a case manager)
Number of subjects: 0
Study 27169436 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 24646921 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-shift training (WST)
Number of subjects: 18
Study 22659765 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gentamicin-collagen sponge plus standard of care
Number of subjects: 56
Study 22659765 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only (control group)
Number of subjects: 56
Study 19920832 — intervention group
Group type: COMPARATOR
Intervention: XELOX
Number of subjects: 306
Study 17584482 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) in the priming solution
Number of subjects: 30
Study 17584482 — intervention group
Group type: COMPARATOR
Intervention: Zero-balance ultrafiltration (ZBUF) during CPB
Number of subjects: 30
Study 15805350 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive regional hospital-based parent education program about violent infant shaking, administered at the time of the child's birth.
Number of subjects: 94209
Study 15805350 — intervention group
Group type: COMPARATOR
Intervention: Follow-up telephone interviews conducted 7 months after birth to assess parents' recall of the information.
Number of subjects: 94209
Study 11960949 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anesthetic
Number of subjects: 37
Study 11960949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 microg/kg iv)
Number of subjects: 37
Study 11960949 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal CO2 exceeding 50 Torr
Number of subjects: 37
Study 9871429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg orally once a day for 5 days, followed by 80 mg tamoxifen on the sixth day.
Number of subjects: 19
Study 9871429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg orally once a day for 5 days, followed by 120 mg toremifene on the sixth day.
Number of subjects: 19
Study 9871429 — intervention group
Group type: COMPARATOR
Intervention: N/A (placebo phase)
Number of subjects: 19
Study 7610930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 1,25(OH)2D (Rocaltrol) 0.5 microgram twice a day for 5 days
Number of subjects: 24
Study 2694180 — intervention group
Group type: EXPERIMENTAL
Intervention: arbaprostil 10 mcg
Number of subjects: 4
Study 2694180 — intervention group
Group type: EXPERIMENTAL
Intervention: arbaprostil 25 mcg
Number of subjects: 4
Study 2694180 — intervention group
Group type: EXPERIMENTAL
Intervention: arbaprostil 50 mcg
Number of subjects: 4
Study 2694180 — intervention group
Group type: EXPERIMENTAL
Intervention: arbaprostil 400 mcg
Number of subjects: 4
Study 2694180 — intervention group
Group type: EXPERIMENTAL
Intervention: arbaprostil 1200 mcg
Number of subjects: 4
Study 2694180 — intervention group
Group type: EXPERIMENTAL
Intervention: arbaprostil 1600 mcg
Number of subjects: 4
Study 154747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 13
Study 154747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 13
Study 154747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide plus sodium cromoglycate
Number of subjects: 13
Study 154747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31183766 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendees of the breast cancer screening program
Number of subjects: 502
Study 31183766 — intervention group
Group type: COMPARATOR
Intervention: Non-attendees of the breast cancer screening program
Number of subjects: 502
Study 31183766 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 61
Number of subjects: 502
Study 31183766 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving the invitation letter
Number of subjects: 502
Study 31183766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to participate
Number of subjects: 502
Study 30877042 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28403412 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafascial catheter tip placement
Number of subjects: 70
Study 28403412 — intervention group
Group type: COMPARATOR
Intervention: Intrafascial catheter tip placement
Number of subjects: 70
Study 23532371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiprosthesis
Number of subjects: 134
Study 23532371 — intervention group
Group type: COMPARATOR
Intervention: Non-cemented hemiprosthesis
Number of subjects: 134
Study 21893693 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) 5 mg daily at bedtime
Number of subjects: 60
Study 21893693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19352213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 30076
Study 17047538 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage procedure (Group A)
Number of subjects: 24
Study 17047538 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage procedure (Group B)
Number of subjects: 24
Study 14557857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-titrated therapy (flunitrazepam, clonidine, haloperidol adjusted as needed)
Number of subjects: 44
Study 14557857 — intervention group
Group type: COMPARATOR
Intervention: Infusion-titrated therapy (continuous infusion of flunitrazepam, clonidine, haloperidol)
Number of subjects: 44
Study 11789278 — intervention group
Group type: EXPERIMENTAL
Intervention: Weikangfu granule (WKF)
Number of subjects: 61
Study 11789278 — intervention group
Group type: COMPARATOR
Intervention: Weisu granule (control)
Number of subjects: 61
Study 9120151 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity S1 stimulation
Number of subjects: 40
Study 9120151 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity S1 stimulation at HLRA
Number of subjects: 40
Study 9120151 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity S1 stimulation at DCS
Number of subjects: 40
Study 9120151 — intervention group
Group type: COMPARATOR
Intervention: Propranolol and autonomic blockade
Number of subjects: 40
Study 9120151 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 40
Study 8268342 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (500 mg daily for 3 days)
Number of subjects: 400
Study 8268342 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (500 mg daily for 6 days)
Number of subjects: 400
Study 8268342 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (total dose of 1,500 mg over 3 days)
Number of subjects: 400
Study 3804184 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 7
Study 3804184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29609656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health continuous quality improvement (CQI) program
Number of subjects: 41
Study 29609656 — intervention group
Group type: EXPERIMENTAL
Intervention: Action plan setting, Systems Assessment Tool, STRIVE coordinator role
Number of subjects: 41
Study 29609656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated funding for health promotion and service incentive payments
Number of subjects: 41
Study 29609656 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI program
Number of subjects: 41
Study 27084926 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by doing (actual performance)
Number of subjects: 0
Study 27084926 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by observing (observation)
Number of subjects: 0
Study 27084926 — intervention group
Group type: COMPARATOR
Intervention: Post-training performance of a second sequence
Number of subjects: 0
Study 27084926 — intervention group
Group type: COMPARATOR
Intervention: Post-training observation of a second sequence
Number of subjects: 0
Study 25064389 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary perineal wound closure with neo-adjuvant (chemo)radiotherapy
Number of subjects: 136
Study 25064389 — intervention group
Group type: EXPERIMENTAL
Intervention: Extralevator approach
Number of subjects: 136
Study 25064389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative perforation
Number of subjects: 136
Study 25064389 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent presacral sinus
Number of subjects: 136
Study 25064389 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal hernia
Number of subjects: 136
Study 25064389 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal wound complications
Number of subjects: 136
Study 22419422 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet cupping combined with dietary advice
Number of subjects: 126
Study 22419422 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice only (Control)
Number of subjects: 126
Study 20728227 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine with epinephrine
Number of subjects: 20
Study 20728227 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 20
Study 19062725 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus epirubicin (TE)
Number of subjects: 88
Study 19062725 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin (TP)
Number of subjects: 88
Study 17012871 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T/HBV10
Number of subjects: 60
Study 17012871 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMPC/HBV15
Number of subjects: 60
Study 17012871 — intervention group
Group type: COMPARATOR
Intervention: Licensed vaccine (DTaP-IPV//PRP-T)
Number of subjects: 60
Study 11901037 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal embolic protection device
Number of subjects: 801
Study 11901037 — intervention group
Group type: COMPARATOR
Intervention: Conventional 0.014-inch angioplasty guidewire (control group)
Number of subjects: 801
Study 10447904 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion in conjunction with epidural ropivacaine and isoflurane anaesthesia
Number of subjects: 0
Study 7599325 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cell activity against K562 cells in children from contaminated areas
Number of subjects: 713
Study 7599325 — intervention group
Group type: COMPARATOR
Intervention: Comparative analysis of NK cell activity in children from contaminated vs non-contaminated areas
Number of subjects: 713
Study 7599325 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of NK cell activity and number
Number of subjects: 713
Study 7599325 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of NK cell activity and body content of 137Cs
Number of subjects: 713
Study 2083041 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan and 2% copolymer)
Number of subjects: 108
Study 6775827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoxan
Number of subjects: 59
Study 6775827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethylmelamine
Number of subjects: 59
Study 6775827 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 59
Study 30884045 — intervention group
Group type: EXPERIMENTAL
Intervention: P11‐4 (Curodont Repair, Credentis AG, Switzerland)
Number of subjects: 32
Study 30884045 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACFP (MI Varnish, GCCo., Japan)
Number of subjects: 32
Study 30884045 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF (Duraphat Varnish, Colgate, Colgate‐Palmolive, NY, USA)
Number of subjects: 32